Efficacy and safety evaluation of tenofovir/lamivudine/efavirenz triplet regimen for treatment of HBV/HIV coinfection
- VernacularTitle:替诺福韦、拉米夫定、依非韦伦联合治疗 HBV／HIV合并感染的疗效和安全性
- Author:
Hui YANG
;
Xiangyun LEI
;
Lian YANG
- Publication Type:Journal Article
- Keywords:
antiretroviral therapy;
hepatitis B virus;
human immunodeficiency virus
- From:
Chinese Journal of Infection and Chemotherapy
2014;(2):132-134
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of tenofovir (TDF)+ lamivudine (3TC)+ efavirenz (EFV)combina-tion therapy in the treatment of HBV/HIV coinfection and provide evidence for effective management of HBV/HIV coinfec-tion.Methods All the AIDS/HIV patients treated in our hospital from February 2011 to October 2011 were screened for eligi-bility in this analysis.Twenty eligible patients with HBV/HIV coinfection were treated with the TDF/3TC/EFV triplet regi-men.The efficacy and safety of the combination therapy were evaluated.Results Of the 15 patients who had completed study period of 48 weeks,all had conversion of HBV DNA to negative,2 had HBeAg seroconversion.The liver function tests were normal.HIV-RNA was below the limit of detection in 15 cases.CD4+ increased by 139.72±3.36/μL on average.The creati-nine and lactate levels were within normal limits.No adverse events were reported.Conclusions The TDF/3TC/EFV triplet regimen is safe and effective for treatment of HBV/HIV coinfection.It is appropriate to recommend this regimen as a standard therapy for HBV/HIV coinfection.
